Elon Musk’s brain implant company, Neuralink, has seen its valuation skyrocket following its successful first human trial, leading some employees to prepare for a stock sale. The company is expected to launch a tender offer next month to buy back shares from employees who wish to cash in on the recent surge in value.
Neuralink’s valuation has more than doubled since last year, fueled by the successful trial and investor confidence in the company’s potential. Employees who received stock compensation at the company’s inception stand to gain a significant windfall. While Neuralink prefers employees to sell through controlled tender offers, some have been turning to private exchanges to sell their shares.
Advertisement
Hey there! Want to support us? If you’re planning on shopping on Amazon, please consider using amzn.to/4bPDFNL. It doesn’t cost you anything extra, but helps us keep the lights on. Thanks for your support!
However, the company’s limited trading restrictions are designed to maintain control over its investor base and shareholder count. Musk’s practice of creating scarcity in his companies’ shares has also driven demand and high premiums on the secondary market, further incentivizing employees to sell. The expected tender offer provides a chance for employees to liquidate their holdings and realize substantial profits from Neuralink’s success.